Prednisolone
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Prednisolone: From Systemic Corticosteroid Therapy to Alopecia Areata
One-Sentence Summary
Prednisolone is a systemic corticosteroid that is marketed in South Africa as a syrup. The TxGNN model predicts it may be effective for alopecia areata. Support is mostly observational and review-level: 3 of the 16 retrieved trials address alopecia, none has a prednisolone arm, and there are 20 publications, including one placebo-controlled prednisolone pulse study.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, prednisolone is a systemic glucocorticoid with broad anti-inflammatory and immunosuppressive effects. Its efficacy in other inflammatory and autoimmune conditions is well established, and mechanistically it may be applicable to alopecia areata.
Alopecia areata is a T-cell-mediated autoimmune attack on the hair follicle, so suppressing that inflammation is a plausible strategy. One mechanistic study (PMID 30294905) suggests oral pulse steroids may act partly by altering TNF-α levels in serum and tissue.
Relapse after withdrawal and cumulative steroid toxicity limit long-term use. Newer targeted agents, such as JAK inhibitors, are now the focus of most modern trials. The very high TxGNN score is therefore not matched by direct prednisolone trial evidence.
Clinical Trial Evidence
Sixteen trials were retrieved. Most concern systemic lupus erythematosus (SLE) or unrelated conditions and do not test prednisolone, so only the alopecia-related trials are listed. The trial-level relevance grading in the source data was inconsistent with the trial titles and was not relied on here. No SANCTR or PACTR registrations were identified.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01167946 | Phase 4 | Completed | 42 | Oral mega-pulse methylprednisolone (a related corticosteroid) in severe, therapy-resistant alopecia areata; results not summarised in the record |
| NCT07101471 | N/A (observational) | Completed | 296 | Tofacitinib safety and effectiveness in alopecia; participants received it with or without adjuvant prednisolone |
| NCT01017510 | N/A | Unknown | 20 | Needle-free Dermojet vs standard syringe for intralesional treatment of alopecia areata; steroid use not confirmed |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37870096 | 2023 | Network meta-analysis | Cochrane Database Syst Rev | Compares treatments for alopecia areata, including immunosuppressants, hair growth stimulants and contact immunotherapy |
| 30191561 | 2019 | Systematic review | Australas J Dermatol | Evaluates the evidence for systemic treatments in alopecia areata, totalis and universalis; efficacy evidence varies |
| 15692475 | 2005 | Placebo-controlled trial (per title) | J Am Acad Dermatol | Oral pulse prednisolone in alopecia areata; the abstract notes earlier pulse-steroid studies were neither randomised nor placebo-controlled |
| 37992355 | 2023 | Review | Dermatol Pract Concept | Reviews efficacy, relapse rates, side effects and prognostic factors of corticosteroid pulse therapy |
| 36461625 | 2023 | Review | Pediatr Dermatol | Pulse-dose corticosteroid regimens and side effects in children; regimens are not well established |
| 21572877 | 2009 | Cohort/case series | Dermato-endocrinology | Medium-dose prednisolone pulse therapy; effective in early stages but side effects led to discontinuation in some patients |
| 28140540 | 2017 | Cohort/case series | J Dtsch Dermatol Ges | Sequential high- then low-dose systemic steroids in severe childhood alopecia areata; relapse follows discontinuation |
| 35986630 | 2022 | Retrospective cohort | Dermatol Ther | Methylprednisolone alone vs with methotrexate in 26 patients with extensive alopecia areata |
| 32779249 | 2020 | Retrospective study | J Eur Acad Dermatol Venereol | Azathioprine, methotrexate and cyclosporine as steroid-sparing agents in 138 patients with chronic alopecia areata |
| 30294905 | 2019 | Mechanistic study | J Cosmet Dermatol | Suggests TNF-α changes as a possible mechanism of oral pulse steroids |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 38/21.5.1/0125 | Adco prednisolone | Syrup | Not stated in the available data |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale is plausible and steroid pulse therapy is described in the alopecia areata literature. However, no listed trial tests prednisolone in alopecia areata. The direct evidence is observational or review-level, with one older placebo-controlled pulse study. Relapse and steroid toxicity limit long-term use. The SAHPRA package insert safety data are also missing, which blocks safety screening.
To proceed, the following is needed:
- The SAHPRA package insert (warnings, contraindications, approved indications) for Adco prednisolone
- Mechanism of action data from DrugBank
- Appraisal of the 2005 placebo-controlled pulse prednisolone study (PMID 15692475), and any prednisolone-specific RCTs in alopecia areata
- A comparison with JAK inhibitors, given their access and eligibility limits in South Africa
- Confirmation of whether a syrup formulation suits the intended pulse regimens and age groups
- Reconciliation of the missing original-indication field with the registered label
For reference, the same evidence pack ranks idiopathic steroid-sensitive nephrotic syndrome at evidence level L1 (Proceed with Guardrails). That is guideline-standard prednisolone use rather than true repurposing, and it may merit its own review.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.